ES2898476T3 - Compuesto de quinolona y uso del mismo - Google Patents
Compuesto de quinolona y uso del mismo Download PDFInfo
- Publication number
- ES2898476T3 ES2898476T3 ES15837609T ES15837609T ES2898476T3 ES 2898476 T3 ES2898476 T3 ES 2898476T3 ES 15837609 T ES15837609 T ES 15837609T ES 15837609 T ES15837609 T ES 15837609T ES 2898476 T3 ES2898476 T3 ES 2898476T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- methyl
- mmol
- independently
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410442574 | 2014-09-02 | ||
| PCT/CN2015/088799 WO2016034108A1 (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2898476T3 true ES2898476T3 (es) | 2022-03-07 |
Family
ID=55417512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15837609T Active ES2898476T3 (es) | 2014-09-02 | 2015-09-01 | Compuesto de quinolona y uso del mismo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10065928B2 (OSRAM) |
| EP (1) | EP3190104B1 (OSRAM) |
| JP (1) | JP6506390B2 (OSRAM) |
| CN (1) | CN105384687B (OSRAM) |
| AU (1) | AU2015311333B2 (OSRAM) |
| CA (1) | CA2959688C (OSRAM) |
| ES (1) | ES2898476T3 (OSRAM) |
| WO (1) | WO2016034108A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN108069952B (zh) * | 2016-11-08 | 2022-09-27 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN108285460A (zh) * | 2017-01-09 | 2018-07-17 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的药用盐及其制备方法与用途 |
| JP6999469B2 (ja) * | 2018-03-28 | 2022-01-18 | 東京応化工業株式会社 | 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子 |
| WO2021104353A1 (zh) | 2019-11-28 | 2021-06-03 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN111269177B (zh) * | 2019-11-28 | 2023-05-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型 |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN115010663A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010662B (zh) * | 2021-03-05 | 2023-12-08 | 广东东阳光药业股份有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010664A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN114989085B (zh) * | 2022-05-23 | 2023-11-24 | 安徽医科大学 | 一种芳基内酰胺环类化合物、药物组合物及其应用 |
| CN117159549B (zh) * | 2023-10-11 | 2025-02-14 | 中国药科大学 | 一种酯类化合物的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004031114D1 (de) * | 2003-06-06 | 2011-03-03 | Fibrogen Inc | Stickstoffhaltige heteroarylverbindungen und deren verwendungen zur erhoehung des gehaltes von endogenem erythropoietin |
| JPWO2006088246A1 (ja) * | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | Ｇｐｒ３４受容体機能調節剤 |
| ATE513833T1 (de) | 2005-03-02 | 2011-07-15 | Fibrogen Inc | Thienopyridinverbindungen und verfahren zu ihrer verwendung |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| AU2006326662B2 (en) * | 2005-12-09 | 2011-07-28 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| CN101374815B (zh) | 2006-01-27 | 2013-07-17 | 菲布罗根有限公司 | 使低氧诱导因子（hif）稳定的氰基异喹啉化合物 |
| TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| KR101084635B1 (ko) | 2006-04-04 | 2011-11-18 | 피브로겐, 인크. | Ｈｉｆ 조절제로서 피롤로- 및 티아졸로-피리딘 화합물 |
| US20090176825A1 (en) | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| AR061570A1 (es) | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| ATE485264T1 (de) | 2006-06-26 | 2010-11-15 | Warner Chilcott Co Llc | Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| AU2007334321B2 (en) | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| EP2111399A2 (en) | 2006-12-18 | 2009-10-28 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| AU2008241483B2 (en) | 2007-04-18 | 2011-03-24 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| AU2008241503A1 (en) * | 2007-04-18 | 2008-10-30 | Merck Sharp & Dohme Corp. | Novel 1,8-naphthyridine compounds |
| US8030346B2 (en) | 2007-05-04 | 2011-10-04 | Amgen Inc. | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity |
| KR20100045480A (ko) | 2007-08-10 | 2010-05-03 | 크리스탈지노믹스(주) | 피리딘 유도체 및 이들의 사용방법 |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009073497A2 (en) | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| WO2009086044A1 (en) | 2007-12-19 | 2009-07-09 | Smith Kline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| US8471024B2 (en) | 2008-02-25 | 2013-06-25 | Merck Sharp & Dohme, Corp. | Tetrahydrofuropyridones |
| AU2009217543A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydro-1H-pyrrolo fused pyridones |
| AU2009217541A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrothieno pyridines |
| WO2009134750A1 (en) | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
| JP2011519858A (ja) | 2008-04-30 | 2011-07-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラ−ゼ阻害剤 |
| WO2009134847A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2306828A4 (en) | 2008-06-25 | 2011-06-29 | Glaxosmithkline Llc | INHIBITORS OF PROLYL HYDROXYLASES |
| CN102264740B (zh) | 2008-08-20 | 2014-10-15 | 菲布罗根有限公司 | 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途 |
| EP2326178A4 (en) | 2008-08-21 | 2012-10-24 | Glaxosmithkline Llc | INHIBITORS OF PROLYL-HYDROXYLASE |
| EP2326179A4 (en) | 2008-08-25 | 2011-08-17 | Smithkline Beecham Corp | PROLYLHYDROXYLASEHEMMER |
| CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| AU2010213814B2 (en) | 2009-02-10 | 2015-07-30 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
| EP2454249B1 (en) | 2009-07-15 | 2018-09-19 | Beijing Betta Pharmaceuticals Co., Ltd | Compounds as hypoxia mimetics, and compositions, and uses thereof |
| HRP20140705T1 (hr) | 2009-07-17 | 2014-09-12 | Japan Tobacco, Inc. | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| TWI500623B (zh) | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| WO2011056725A1 (en) | 2009-11-05 | 2011-05-12 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| US8541430B2 (en) | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
| JP5755741B2 (ja) | 2010-08-13 | 2015-07-29 | ヤンセン ファーマシューティカ エヌ．ベー． | プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物 |
| US8921389B2 (en) | 2011-02-02 | 2014-12-30 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase |
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| NO2686520T3 (OSRAM) | 2011-06-06 | 2018-03-17 | ||
| EP2736892A4 (en) | 2011-07-29 | 2015-03-18 | Beijing Betta Pharmaceuticals Co Ltd | STABLE POLYMORPHIC FORMS OF A CONNECTION AS HYPOXIEMIMETICS AND USES THEREOF |
| JP6129217B2 (ja) | 2012-03-09 | 2017-05-17 | フィブロジェン インコーポレイテッド | Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物 |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| CN103435546B (zh) | 2012-07-16 | 2016-08-10 | 菲布罗根有限公司 | 制备异喹啉化合物的方法 |
| CN104507910B (zh) | 2012-07-30 | 2016-06-15 | 大正制药株式会社 | 部分饱和的含氮杂环化合物 |
| US20150239889A1 (en) | 2012-08-23 | 2015-08-27 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compound |
| MY175854A (en) * | 2012-12-24 | 2020-07-14 | Cadila Healthcare Ltd | Novel quinolone derivatives |
| RU2666144C2 (ru) | 2013-01-24 | 2018-09-06 | Фиброген, Инк. | Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты |
-
2015
- 2015-09-01 CA CA2959688A patent/CA2959688C/en active Active
- 2015-09-01 US US15/502,499 patent/US10065928B2/en active Active
- 2015-09-01 CN CN201510557206.9A patent/CN105384687B/zh active Active
- 2015-09-01 AU AU2015311333A patent/AU2015311333B2/en active Active
- 2015-09-01 WO PCT/CN2015/088799 patent/WO2016034108A1/zh not_active Ceased
- 2015-09-01 ES ES15837609T patent/ES2898476T3/es active Active
- 2015-09-01 JP JP2017512046A patent/JP6506390B2/ja active Active
- 2015-09-01 EP EP15837609.5A patent/EP3190104B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3190104B1 (en) | 2021-10-27 |
| CA2959688C (en) | 2024-02-27 |
| EP3190104A1 (en) | 2017-07-12 |
| AU2015311333B2 (en) | 2017-11-16 |
| WO2016034108A1 (zh) | 2016-03-10 |
| US10065928B2 (en) | 2018-09-04 |
| AU2015311333A1 (en) | 2017-02-16 |
| CN105384687A (zh) | 2016-03-09 |
| CN105384687B (zh) | 2018-05-01 |
| CA2959688A1 (en) | 2016-03-10 |
| JP2017525737A (ja) | 2017-09-07 |
| EP3190104A4 (en) | 2018-04-11 |
| US20170247332A1 (en) | 2017-08-31 |
| JP6506390B2 (ja) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2898476T3 (es) | Compuesto de quinolona y uso del mismo | |
| WO2021027911A1 (zh) | 新型螺环类K-Ras G12C抑制剂 | |
| WO2023280136A1 (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| ES2714100T3 (es) | Compuestos de quinolina fusionados como inhibidores de mTor, pi3k | |
| CA3136989A1 (en) | Pyrrole amide compound and use thereof | |
| WO2024212670A1 (zh) | 乙烯基吡喃酮类化合物及其在治疗阿尔茨海默病中的应用 | |
| ES2928666T3 (es) | Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas | |
| CN108239074A (zh) | 喹唑啉类化合物及其制备方法、用途和药物组合物 | |
| WO2019084300A1 (en) | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | |
| CN108069952B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN112851647B (zh) | 布雷菲德菌素a衍生物及其制备方法和用途 | |
| CN104387358B (zh) | 淫羊藿苷类化合物及其应用 | |
| CN110156782A (zh) | 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物 | |
| CN112851648B (zh) | 布雷菲德菌素a酯类衍生物在抗肿瘤药物中的应用 | |
| CN104387430B (zh) | 淫羊藿苷类化合物及其应用 | |
| CN108069957B (zh) | 脯氨酰羟化酶抑制剂及其用途 | |
| WO2024099225A1 (zh) | Ulk抑制剂 | |
| CN104402833B (zh) | 含有环丁烷取代基的吡嗪类化合物及其组合物及用途 | |
| CA3067871A1 (en) | Anti-cancer/anti-fibrosis compounds | |
| CN118302418A (zh) | 一种芳杂环类化合物及其应用 | |
| CN115232147A (zh) | 一种作为HIF-2α激动剂的杂环衍生物 | |
| WO2017180723A1 (en) | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use | |
| WO2022063333A1 (zh) | 一种嘧啶甲酰胺类化合物及其应用 | |
| ES2548789B1 (es) | Nuevas cromenoquinonas moduladoras de receptores cannabinoidescb2 con actividad antitumoral | |
| TW202540096A (zh) | 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途 |